Balloon trick during cancer surgery may prevent stomach troubles
NCT ID NCT07355374
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether inflating a small balloon in the pylorus (the valve between stomach and small intestine) during minimally invasive esophageal cancer surgery can prevent delayed stomach emptying, a common complication. About 116 patients will be randomly assigned to receive the balloon dilation or standard surgery alone. The main goal is to see if the procedure reduces stomach emptying problems within the first two weeks after surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- endoscopic pylorus balloon dilation
- What this could lead to
- If effective, this simple procedure could become a standard addition to esophagectomy, reducing complications and speeding recovery.
- What could go wrong
- This is a single-center trial with 116 patients, so results may not apply broadly. The procedure also carries rare risks like perforation or bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 116 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2025
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \>18 years * Histologically confirmed esophageal cancer * Planned surgical resection in curative intent as a minimally invasive Ivor Lewis procedure * Provided informed consent Exclusion Criteria: * Prior esophageal or gastric resection * Non-curative intent of surgery * ASA Score V * Patients lacking capacity to provide informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Delayed gastric conduit emtpying (DGCE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Clarunis University Digestive Health Care Center Basel
RECRUITINGBasel, Canton of Basel-City, 4058, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Patient's own blood turned into surgical glue to stop deadly leaks
- Blood proteins may predict who beats esophageal cancer with chemoradiation
- Blood test aims to catch Cancer's return earlier
- Can a new pill boost Immunotherapy's power against advanced tumors?
- Can Direct-to-Abdomen chemotherapy tame GI cancers that spread?
- Can new tracers make many cancers light up on scans?